1. Home
  2. SEPN

as 05-09-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

NYSE

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Founded: 2022 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 311.6M IPO Year: 2024
Target Price: $33.00 AVG Volume (30 days): 181.2K
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -7.26 EPS Growth: N/A
52 Week Low/High: $4.17 - $28.99 Next Earning Date: 05-19-2025
Revenue: $1,075,000 Revenue Growth: 611.92%
Revenue Growth (this year): -66.79% Revenue Growth (next year): N/A

Share on Social Networks: